Fritz C. Eilber

7.7k citations
121 papers · 5.0k indexed · h-index 41

Fritz C. Eilber

115 papers receiving 4.9k citations

Peers

Fritz C. Eilber
Comparison fields: 5 of 109
  • Biotechnology 980
  • Pulmonary and Respiratory Medicine 3.0k
  • Rheumatology 1.0k
  • Oncology 1.8k
  • Cardiology and Cardiovascular Medicine 965
Replace Takafumi Ueda with:
Takafumi Ueda Japan
Barbara Dockhorn‐Dworniczak Germany
Alessandra Longhi Italy
Sophie Piperno‐Neumann France
Mary Louise Keohan United States
Maija Tarkkanen Finland
Makio Mukai Japan
Louis Guillou Switzerland
Ira J. Spiro United States
André M. Oliveira United States
Fritz C. Eilber relative to Takafumi Ueda Japan Takafumi Ueda's profile →
Citations per field
00.5×10×13.4×
Takafumi Ueda · 1×
Citations per year

Countries citing papers authored by Fritz C. Eilber

Since Specialization
Citations

This map shows the geographic impact of Fritz C. Eilber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fritz C. Eilber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fritz C. Eilber more than expected).

Fields of papers citing papers by Fritz C. Eilber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fritz C. Eilber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fritz C. Eilber. The network helps show where Fritz C. Eilber may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Fritz C. Eilber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fritz C. Eilber Line = papers co-authored together Fritz C. Eilber links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20240
2 20233
3 20232
4 202316
5 20212
6 202077
7 202043
8 201826
9 201815
10 201817
11 201817
12 20173
13 201446
14 201327
15 201322
16 201227
17 2012131
18 20118
19 20075
20 200613

About Fritz C. Eilber

Fritz C. Eilber is a scholar working on Biotechnology, Pulmonary and Respiratory Medicine and Oncology, having authored 121 papers that have together received 5.0k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (77 papers), Cancer Research and Treatments (36 papers), Nanoplatforms for cancer theranostics (29 papers), Virus-based gene therapy research (26 papers), Vascular Tumors and Angiosarcomas (20 papers), Bone Tumor Diagnosis and Treatments (17 papers), CAR-T cell therapy research (13 papers) and Cardiac tumors and thrombi (12 papers). The work is most often cited by research in Biotechnology (980 citations), Pulmonary and Respiratory Medicine (3.0k citations) and Rheumatology (1.0k citations). Fritz C. Eilber has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Sarah Dry, Frederick R. Eilber, Scott D. Nelson, William D. Tap, J J Eckardt, Arun S. Singh, Gerald Rosen, Johannes Czernin, Noah Federman and Nicholas M. Bernthal. Their work appears in journals such as Oncotarget, Cell Cycle, Journal of Cellular Biochemistry, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026